– USA, NJ – Akers Biosciences, Inc. (NASDAQ: AKER) (AIM:AKR.L), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, is pleased to announce the appointment of former congressman Robert E. “Rob” Andrews as a Non-executive Director of the Company. Mr. Andrews served as a Member of the U.S. House of Representatives from 1990 to 2014 as the Representative for New Jersey’s 1st congressional district.
During his time in the U.S. House of Representatives, Mr. Andrews served on the Committee on Armed Services, Committee on the Budget, and Committee on Education and Labor, where he served as Chairman of the Subcommittee on Health, Employment, Labor, and Pensions.
Mr. Andrews was a candidate for the Democratic nomination in the 2008 U.S. Senate election.
Mr. Andrews retired from the House in 2014 to take the position as Of Counsel at Dilworth Paxson LLP where he also chairs the Government Affairs Group. Mr. Andrews attended Cornell Law School from which he graduated magna cum laude in 1982.
“Rob has a deep understanding of the U.S. healthcare system,” said Raymond F. Akers, Jr. PhD, Co. founder and Executive Chairman. “Upon his departure from the House, President Obama praised his service as “an original author of the Affordable Care Act…and a vital partner in its passage and implementation.” With more Americans than ever gaining coverage, and Akers Bio producing reimbursable rapid diagnostic screening tests aimed at major medical conditions, Rob’s perspective and understanding will be extremely valuable to the Company,” continued Dr. Akers. “It is an honor to welcome Rob to the Board of Directors,” added Dr. Akers.
In addition, Mr. Andrews was appointed to the Company’s Governance and Nominating Committee, Compensation Committee and Audit Committee; and will serve as the Chairman of the Company’s Compensation Committee.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost‐effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company’s state‐of‐the‐art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
